heart attack
NHS to pioneer Novartis injection that reduces cholesterol
January 14, 2020Manufacturing and Production NHS, NHS England, bad cholesterol, cholesterol, heart attack
The NHS in England is pioneering a new twice-a-year injection, inclisiran, which reduces bad cholesterol.It has reached a deal with …
“Triple pill” blood pressure combo proves more effective, safe than standard care
August 16, 2018Research and Development blood pressure, heart attack, heart disease, pharma, triple pill
A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating …
Researchers design new class of drugs to counter cardiovascular disease
August 14, 2018Manufacturing and Production TMAO, cardiovascular, gut microbe, heart attack, research
Cleveland Clinic researchers have designed a potential new class of drugs that may reduce the risk of cardiovascular disease by …
Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack
March 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma
Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …
AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3
March 12, 2018Research and Development, Sales and Marketing AstraZeneca, Brilinta, heart attack
AstraZeneca has revealed new Phase 3 data on its direct-acting P2Y12 receptor antagonist Brilinta (ticagrelor) at the American College of …
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
Improved heart attack test could save millions for NHS
September 27, 2017Research and Development biotech, drugs, heart attack, pharma, pharmaceutical
A new research, funded by the British Heart Foundation, has led to the creation of a new heart attack test …
AstraZeneca’s Brilinta protects against adverse cardiovascular events for up to 5 years, new data reveals
September 7, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, pharma, pharmaceutical, ticagrelor, trial
AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …
12% of the UK have hearts ten years older than they are, Public Health England finds
September 4, 2017Research and Development, Sales and Marketing British Heart Foundation, Public Health England, cardiovascular disease, heart attack, heart health, stroke
New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are …
MSD scores trial success in reducing cardiovascular risk
August 29, 2017Manufacturing and Production, Research and Development MSD, heart attack, heart disease, life sciences, pharma, pharmaceutical
New data on MSD’s anacetrapib has revealed that the drug was able to reduce risk of the risk of major …
Extended use of AstraZeneca’s Brilinta reduces cardiovascular death risk
August 24, 2017Research and Development AstraZeneca, Brilinta, cardiovascular, heart attack, life sciences, pharma, pharmaceutical
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk …
Beta blockers offer little to no benefit for heart attack patients, study suggests
May 30, 2017Manufacturing and Production, Research and Development beta-blockers, heart attack
New research from the University of Leeds has called into question the prevalent practice of prescribing beta blockers for heart …
TiGenix announces success of novel heart attack stem cell trial
March 13, 2017Research and Development, Sales and Marketing Stem cells, TiGenix, heart attack
Belgium’s TiGenix has announced the success of its top-line Phase 2/3 study investigating the effects of donor-derived expanded cardiac stem …
AstraZeneca’s post-heart attack drug gets NICE recommendation
November 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure
April 20, 2016Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
Latest content
FibroFind appoints Lee Borthwick as CEO
